Mifepristone (Ru486) antagonizes monocyte chemotactic protein-3 down-regulation at early mouse pregnancy revealing immunomodulatory events in Ru486 induced abortion

American Journal of Reproductive Immunology

Volumn 52, Issue 1, 2004, Pages 8-18

  Nautiyal, Jaya ^a   Kumar, Pradeep G ^a   Laloraya, Malini ^a  

^a DEVI AHILYA UNIVERSITY   (India)

Author keywords

Abortificient; Embryo implantation; Estrogen; Monocyte Chemotactic Protein 3; Progesterone; RU486; Th1 Th2 ratio

Indexed keywords

ABORTIVE AGENT; ANTIGESTAGEN; ANTINEOPLASTIC AGENT; BETA CHEMOKINE; MIFEPRISTONE; MONOCYTE CHEMOTACTIC PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DELAYED IMPLANTATION; DOWN REGULATION; DRUG MECHANISM; FEMALE; FIRST TRIMESTER PREGNANCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; INDUCED ABORTION; MOUSE; NIDATION; NONHUMAN; PREIMPLANTATION EMBRYO; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; UTERUS; WESTERN BLOTTING;

EID: 3543108351     PISSN: 10467408     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2004.00176.x     Document Type: Article

References (48)

1. Simon C, Frances A, Lee BY, Mercader A, Huynh T, Remohi J, Polan ML, Pellicer A: Immunohistochemical localization, identification and regulation of the interleukin-1 receptor antagonist in the human endometrium. Hum Reprod 1995; 10:2472-2477.
2. Baggiolini M, Dewald B, Moser B: Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994; 55:97-179.
3. Baggiolini M: Chemokines in pathology and medicine. J Intern Med. 2001; 250:91-104.
4. Simon C, Caballero-Campo P, Garcia-Velasco JA, Pellicer A: Potential implications of chemokines in reproductive function: an attractive idea. J Reprod Immunol 1998; 38:169-193.
5. Pollard JW: Regulation of polypeptide growth factor synthesis and growth factor-related gene expression in the rat and mouse uterus before and after implantation. J Reprod Fertil 1990; 88:721-731.
6. Robertson SA, Brannstrom M, Seamark RF: Cytokines in rodent reproduction and the cytokine-endocrine interaction. Curr Opin Immunol 1992; 4:585-590.
7. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2:123-128.
8. Van Damme J, Proost P, Lenaerts JP, Opdenakker G: Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992; 176:59-65.
9. Sozzani S, Zhou D, Locati M, Rieppi M, Proost P, Magazin M, Vita N, Van Damme J, Mantovani A: Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J Immunol 1994; 152:3615-3622.
10. Dahinden CA, Geiser T, Brunner T, von TV, Caput D, Ferrara P, Minty A, Baggiolini M: Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 1994; 179:751-756.
11. Sozzani S, Sallusto F, Luini W, Zhou D, Piemonti L, Allavena P, Van Damme J, Valitutti S, Lanzavecchia A, Mantovani A: Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 1995; 155:3292-3295.
12. Arici A, Senturk LM, Seli E, Bahtiyar MO, Kim G: Regulation of monocyte chemotactic protein-1 expression in human endometrial stromal cells by estrogen and progesterone. Biol Reprod 1999; 61:85-90.
13. Saxena D, Purohit SB, Kumer GP, Laloraya M: Increased appearance of inducible nitric oxide synthase in the uterus and embryo at implantation. Nitric Oxide 2000; 4:384-391.
14. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
15. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 1992; 24:145-149.
16. Simon C, Valbuena D: Embryonic implantation. Ann Endocrinol (Paris) 1999; 60:134-136.
17. Jones RK, Bulmer JN, Searle RF: Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod 1995; 10:3272-3279.
18. King A, Gardner L, Loke YW: Evaluation of oestrogen and progesterone receptor expression in uterine mucosal lymphocytes. Hum Reprod 1996; 11:1079-1082.
19. Szekeres-Bartho J, Reznikoff-Etievant MF, Varga P, Pichon MF, Varga Z, Chaouat G: Lymphocytic progesterone receptors in normal and pathological human pregnancy. J Reprod Immunol 1989; 16:239-247.
20. Chiu L, Nishimura M, Ishii Y, Nieda M, Maeshima M, Takedani Y, Shibata Y, Tadokoro K, Juji T: Enhancement of the expression of progesterone receptor on progesterone-treated lymphocytes after immunotherapy in unexplained recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35:552-557.
21. Robertson SA, Seamark RF, Guilbert LJ, Wegmann TG: The role of cytokines in gestation. Crit Rev Immunol 1994; 14:239-292.
22. King A, Loke YW: The influence of the maternal uterine immune response on placentation in human subjects. Proc Nutr Soc 1999; 58:69-73.
23. Swain SL: Lymphokines and the immune response: the central role of interleukin-2. Curr Opin Immunol 1991; 3:304-310.
24. Mosmann TR, Coffman RL: Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46:111-147.
25. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG: Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993; 151:4562-4573.
26. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353-356.
27. Szekeres-Bartho J, Varga P, Kinsky R, Chaouat G: Progesterone-mediated immunosuppression and the maintenance of pregnancy. Res Immunol 1990; 141:175-181.
28. Saito S: Cytokine network at the feto-maternal interface. J Reprod Immunol 2000; 47:87-103.
29. Polgar B, Kispal G, Lachmann M, Paar G, Nagy E, Csere P, Miko E, Szereday L, Varga P, Szekeres-Bartho J: Molecular cloning and immunologic characterization of a novel cDNA coding for progesterone-induced blocking factor. J Immunol 2003; 171:5956-5963.
30. Szekeres-Bartho J, Faust Z, Varga P: The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Am J Reprod Immunol 1995; 34:342-348.
31. Szekeres-Bartho J, Faust Z, Varga P, Szereday L, Kelemen K: The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol 1996; 35:348-351.
32. Szekeres-Bartho J, Barakonyi A, Polgar B, Par G, Faust Z, Palkovics T, Szereday L: The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 1999; 42:44-48.
33. Szekeres-Bartho J, Barakonyi A, Par G, Polgar B, Palkovics T, Szereday L: Progesterone as an immunomodulatory molecule. Int Immunopharmacol 2001; 1:1037-1048.
34. Choi BC, Polgar K, Xiao L, Hill JA: Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000; 15:46-59.
35. Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A: Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 1998; 161:342-346.
36. Ulmann A, Teutsch G, Philibert D: RU 486. Sci Am 1990; 262:42-48.
37. Baulieu EE: Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 1989; 245:1351-1357.
38. Nieman LK, Choate TM, Chrousos GP, Healy DL, Morin M, Renquist D, Merriam GR, Spitz IM, Bardin CW, Baulieu EE: The progesterone antagonist RU 486. A potential new contraceptive agent. N Engl J Med 1987; 316:187-191.
39. Spitz IM, Bardin CW: Clinical pharmacology of RU 486 - an antiprogestin and antiglucocorticoid. Contraception 1993; 48:403-444.
40. Spitz IM, Bardin CW: Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404-412.
41. Spitz IM, Croxatto HB, Robbins A: Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996; 36:47-81.
42. Agarwal SK, Marshall GD Jr: Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J Interferon Cytokine Res 1998; 18:1059-1068.
43. Denison FC, Riley SC, Elliott CL, Kelly RW, Calder AA, Critchley HO: The effect of mifepristone administration on leukocyte populations, matrix metalloproteinases and inflammatory mediators in the first trimester cervix. Mol Hum Reprod 2000; 6:541-548.
44. Leech M, Hutchinson P, Holdsworth SR, Morand EF: Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clin Exp Immunol 1998; 112:383-388.
45. Kashiwagi M, Masutani K, Shinozaki M, Hirakata H: MCP-1 and RANTES are expressed in renal cortex of rats chronically treated with nitric oxide synthase inhibitor. Involvement in macrophage and monocyte recruitment. Nephron 2002; 92:165-173.
46. Gagioti S, Scavone C, Bevilacqua E: Participation of the mouse implanting trophoblast in nitric oxide production during pregnancy. Biol Reprod 2000; 62:260-268.
47. Novaro V, Gonzalez E, Jawerbaum A, Rettori V, Canteros G, Gimeno MF: Nitric oxide synthase regulation during embryonic implantation. Reprod Fertil Dev 1997; 9:557-564.
48. Ben Baruch A, Xu L, Young PR, Bengali K, Oppenheim JJ, Wang JM: Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protem-1 alpha/Rantes, is also a functional receptor for MCP3. J Biol Chem 1995; 270:22123-22128.